Network meta-analysis suggests that venetoclax plus azacitidine may provide superior overall survival compared to IDH inhibitor combinations in IDH-mutated AML, though direct comparative studies are needed to confirm these findings [22]. This evidence concerns the gene IDH2 and acute myeloid leukemia.